These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 21437708)
21. Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes. Gałczyńska K; Drulis-Kawa Z; Arabski M Molecules; 2020 Jul; 25(15):. PubMed ID: 32751963 [TBL] [Abstract][Full Text] [Related]
22. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells. Turella P; Filomeni G; Dupuis ML; Ciriolo MR; Molinari A; De Maria F; Tombesi M; Cianfriglia M; Federici G; Ricci G; Caccuri AM J Biol Chem; 2006 Aug; 281(33):23725-32. PubMed ID: 16769721 [TBL] [Abstract][Full Text] [Related]
23. Proapoptotic activity in vitro of two novel ruthenium(II) complexes with flavanone-based ligands that overcome cisplatin resistance in human bladder carcinoma cells. Kasprzak MM; Szmigiero L; Zyner E; Ochocki J J Inorg Biochem; 2011 Apr; 105(4):518-24. PubMed ID: 21334279 [TBL] [Abstract][Full Text] [Related]
24. Insights into anticancer activity and mechanism of action of a ruthenium(II) complex in human esophageal squamous carcinoma EC109 cells. Guo L; Lv G; Qiu L; Yang H; Zhang L; Yu H; Zou M; Lin J Eur J Pharmacol; 2016 Sep; 786():60-71. PubMed ID: 27262377 [TBL] [Abstract][Full Text] [Related]
25. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465 [TBL] [Abstract][Full Text] [Related]
26. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. Chen T; Liu Y; Zheng WJ; Liu J; Wong YS Inorg Chem; 2010 Jul; 49(14):6366-8. PubMed ID: 20527894 [TBL] [Abstract][Full Text] [Related]
27. The induction of apoptosis in HepG-2 cells by ruthenium(II) complexes through an intrinsic ROS-mediated mitochondrial dysfunction pathway. Zeng CC; Lai SH; Yao JH; Zhang C; Yin H; Li W; Han BJ; Liu YJ Eur J Med Chem; 2016 Oct; 122():118-126. PubMed ID: 27344489 [TBL] [Abstract][Full Text] [Related]
28. An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. Meier SM; Kreutz D; Winter L; Klose MHM; Cseh K; Weiss T; Bileck A; Alte B; Mader JC; Jana S; Chatterjee A; Bhattacharyya A; Hejl M; Jakupec MA; Heffeter P; Berger W; Hartinger CG; Keppler BK; Wiche G; Gerner C Angew Chem Int Ed Engl; 2017 Jul; 56(28):8267-8271. PubMed ID: 28547791 [TBL] [Abstract][Full Text] [Related]
29. Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Vidimar V; Meng X; Klajner M; Licona C; Fetzer L; Harlepp S; Hébraud P; Sidhoum M; Sirlin C; Loeffler JP; Mellitzer G; Sava G; Pfeffer M; Gaiddon C Biochem Pharmacol; 2012 Dec; 84(11):1428-36. PubMed ID: 22964219 [TBL] [Abstract][Full Text] [Related]
31. Antitumor Effect of Organometallic Half-Sandwich Ru(II)-Arene Complexes Bearing a Glutathione Han T; Wu Y; Han W; Yan K; Zhao J; Sun Y Inorg Chem; 2021 Sep; 60(17):13051-13061. PubMed ID: 34369147 [TBL] [Abstract][Full Text] [Related]
32. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds. Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645 [TBL] [Abstract][Full Text] [Related]
33. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. Gaiddon C; Jeannequin P; Bischoff P; Pfeffer M; Sirlin C; Loeffler JP J Pharmacol Exp Ther; 2005 Dec; 315(3):1403-11. PubMed ID: 16169939 [TBL] [Abstract][Full Text] [Related]
34. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Brabec V; Nováková O Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363 [TBL] [Abstract][Full Text] [Related]
35. Quantification of bindings of organometallic ruthenium complexes to GSTπ by mass spectrometry. Lin Y; Huang Y; Zheng W; Wu K; Luo Q; Zhao Y; Xiong S; Wang F J Inorg Biochem; 2015 May; 146():44-51. PubMed ID: 25769011 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption. Wan D; Tang B; Wang YJ; Guo BH; Yin H; Yi QY; Liu YJ Eur J Med Chem; 2017 Oct; 139():180-190. PubMed ID: 28800456 [TBL] [Abstract][Full Text] [Related]
37. Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers. Li L; Wong YS; Chen T; Fan C; Zheng W Dalton Trans; 2012 Jan; 41(4):1138-41. PubMed ID: 22159211 [TBL] [Abstract][Full Text] [Related]
38. Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media. Malina J; Novakova O; Keppler BK; Alessio E; Brabec V J Biol Inorg Chem; 2001 Apr; 6(4):435-45. PubMed ID: 11372202 [TBL] [Abstract][Full Text] [Related]
39. Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis. Zheng W; Luo Q; Lin Y; Zhao Y; Wang X; Du Z; Hao X; Yu Y; Lü S; Ji L; Li X; Yang L; Wang F Chem Commun (Camb); 2013 Nov; 49(87):10224-6. PubMed ID: 23856988 [TBL] [Abstract][Full Text] [Related]
40. Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene. Montel AM; Dos Santos RG; da Costa PR; Silveira-Lacerda EP; Batista AA; Dos Santos WG Biometals; 2017 Apr; 30(2):295-305. PubMed ID: 28258507 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]